Exchange: NASDAQ Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
3.73% $6.57
America/New_York / 23 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 18.49 mill |
EPS: | -17.35 |
P/E: | -0.380 |
Earnings Date: | May 07, 2024 |
SharesOutstanding: | 2.82 mill |
Avg Daily Volume: | 0.0210 mill |
RATING 2024-04-23 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Buy | |
Return On Equity: | Strong Sell | |
Return On Asset: | Sell | |
DE: | Strong Buy | |
P/E: | Neutral | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | n/a | n/a | n/a | |||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.380 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.01x |
Company: PE -0.380 | industry: PE 47.78 |
DISCOUNTED CASH FLOW VALUE |
---|
$5.99 (-8.75%) $-0.574 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 6.25 - 6.89 ( +/- 4.81%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-04 | Trachtenberg Eric | Buy | 4 600 | Common Stock |
2024-01-04 | Trachtenberg Eric | Sell | 1 227 | Common Stock |
2024-01-04 | Trachtenberg Eric | Buy | 20 500 | Stock Option (right to buy) |
2024-01-04 | Kharabi Darius | Buy | 4 600 | Common Stock |
2024-01-04 | Kharabi Darius | Sell | 1 385 | Common Stock |
INSIDER POWER |
---|
92.84 |
Last 100 transactions |
Buy: 1 301 269 | Sell: 48 062 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $6.57 (3.73% ) |
Volume | 0.0045 mill |
Avg. Vol. | 0.0210 mill |
% of Avg. Vol | 21.60 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies using its proprietary mucus penetrating particles technology for the treatment of eye diseases. The company's product candidates include KPI-012, which is in clinical development stage for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development products comprise KPI-287 that inhibits the vascular endothelial and platelet derived growth factors for the treatment of retinal diseases, including wet age-related macular degeneration, diabetic macular edema, and retinal vein occlusion; and selective glucocorticoid receptor modulators program, a novel class of compounds to regulate gene expression through the transrepression pathway while avoiding the transactivation pathway. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Watertown, Massachusetts.
Date | Signal | @ |
---|---|---|
WHITEUSD | Apr 24 - 05:08 | 5 473.13 |
HATUSD | Apr 24 - 05:11 | 1 961.58 |
^BSESN | Apr 24 - 04:59 | PTS73 946 |
^STOXX50E | Apr 24 - 04:57 | PTS5 019.78 |
^SDAXI | Apr 24 - 04:57 | 14 280 |
MAVUSD | Apr 24 - 05:09 | 0.450 |
^STOXX | Apr 24 - 04:56 | 508.14 |
^IBEX | Apr 24 - 04:57 | PTS11 068 |
WAWI.OL | Apr 24 - 04:55 | NOK105.30 |
^N100 | Apr 24 - 04:57 | PTS1 523.55 |